Dynavax Technologies (NASDAQ:DVAX) Sets New 52-Week High – Here’s What Happened

Dynavax Technologies Corporation (NASDAQ:DVAX)’s stock price reached a new 52-week high during mid-day trading on Monday . The company traded as high as $15.71 and last traded at $15.6950, with a volume of 2115139 shares trading hands. The stock had previously closed at $15.41.

Wall Street Analysts Forecast Growth

DVAX has been the subject of several analyst reports. Weiss Ratings reissued a “sell (d)” rating on shares of Dynavax Technologies in a research note on Wednesday, October 8th. Wall Street Zen raised Dynavax Technologies from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 27th. Finally, William Blair lowered shares of Dynavax Technologies from an “outperform” rating to a “hold” rating in a research note on Wednesday, December 24th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $24.33.

Dynavax Technologies Price Performance

The company has a market capitalization of $1.85 billion, a PE ratio of -42.49 and a beta of 0.89. The company has a current ratio of 7.62, a quick ratio of 6.94 and a debt-to-equity ratio of 0.41. The stock has a fifty day simple moving average of $12.34 and a 200-day simple moving average of $11.04.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $0.21 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.07. Dynavax Technologies had a positive return on equity of 7.18% and a negative net margin of 13.13%.The business had revenue of $94.88 million for the quarter, compared to the consensus estimate of $94.00 million. Equities analysts anticipate that Dynavax Technologies Corporation will post 0.32 earnings per share for the current year.

Insider Buying and Selling

In other Dynavax Technologies news, COO David F. Novack sold 30,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 24th. The shares were sold at an average price of $15.49, for a total transaction of $464,700.00. Following the sale, the chief operating officer owned 111,451 shares of the company’s stock, valued at approximately $1,726,375.99. This trade represents a 21.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 2.98% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of DVAX. Hantz Financial Services Inc. raised its stake in Dynavax Technologies by 236.9% during the 3rd quarter. Hantz Financial Services Inc. now owns 3,854 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 2,710 shares in the last quarter. LSV Asset Management purchased a new position in shares of Dynavax Technologies during the third quarter worth about $89,000. Osaic Holdings Inc. increased its position in shares of Dynavax Technologies by 15.1% during the second quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company’s stock worth $93,000 after purchasing an additional 1,226 shares in the last quarter. Callan Family Office LLC acquired a new stake in shares of Dynavax Technologies during the second quarter worth about $107,000. Finally, CIBC Bancorp USA Inc. purchased a new stake in shares of Dynavax Technologies in the 3rd quarter valued at about $109,000. Institutional investors and hedge funds own 96.96% of the company’s stock.

About Dynavax Technologies

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.